BCL2 and CLIP2 expression in pediatric healthy vs pAML bone marrow. Diagnostic gene expression of healthy and pAML from the whole TARGET data set was evaluated, regardless of treatment protocols. All patients with AML were subdivided into low, standard, and high-risk groups. The Wilcoxon test was used to compare each AML risk group with healthy individuals, and logistic regression with the risk additive model was used to estimate the OR of gene expression, which increases with risk. BM, bone marrow; ns, not significant.